Literature DB >> 19805558

Correlation between vancomycin MIC values and those of other agents against gram-positive bacteria among patients with bloodstream infections caused by methicillin-resistant Staphylococcus aureus.

N Patel1, P Lubanski, S Ferro, M Bonafede, S Harrington, A Evans, K Stellrecht, T P Lodise.   

Abstract

An increase in the distribution of vancomycin MIC values among methicillin (meticillin)-resistant Staphylococcus aureus (MRSA) isolates has been noted. It is postulated that the shift in vancomycin MIC values may be associated with a concurrent rise in the MIC values of other anti-MRSA agents. Scant data are available on the correlation between vancomycin MIC values and the MIC values of other anti-MRSA agents. This study examined the correlation between vancomycin MIC values and the MIC values of daptomycin, linezolid, tigecycline, and teicoplanin among 120 patients with bloodstream infections caused by MRSA at a tertiary care hospital between January 2005 and May 2007. For each included patient, the MIC values of the antibiotics under study were determined by the Etest method and were separated into the following two categories: day 1 (index) and post-day 1 (subsequent). For subsequent isolates, the MIC values for each antibiotic from the post-day 1 terminal isolate were used. Among the index isolates, there was a significant correlation (P value, <0.01) between the MIC values for vancomycin and daptomycin and between the MIC values for vancomycin and teicoplanin. The MIC values for daptomycin were significantly correlated with linezolid, tigecycline, and teicoplanin MIC values. Among the 48 patients with subsequent isolates, vancomycin MIC values were significantly correlated with MIC values for daptomycin, linezolid, and teicoplanin (rho value of >or=0.38 for all comparisons). This study documented an association between vancomycin MIC values and the MIC values of other anti-MRSA antibiotics among patients with bloodstream infections caused by MRSA primarily treated with vancomycin.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19805558      PMCID: PMC2786352          DOI: 10.1128/AAC.00307-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  14 in total

Review 1.  Adaptation of methicillin-resistant Staphylococcus aureus in the face of vancomycin therapy.

Authors:  George Sakoulas; Robert C Moellering; George M Eliopoulos
Journal:  Clin Infect Dis       Date:  2006-01-01       Impact factor: 9.079

2.  Novel mechanism of antibiotic resistance originating in vancomycin-intermediate Staphylococcus aureus.

Authors:  Longzhu Cui; Akira Iwamoto; Jian-Qi Lian; Hui-min Neoh; Toshiki Maruyama; Yataro Horikawa; Keiichi Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

3.  Improved antimicrobial activity of linezolid against vancomycin-intermediate Staphylococcus aureus.

Authors:  Yukiko Watanabe; Hui-Min Neoh; Longzhu Cui; Keiichi Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  2008-08-18       Impact factor: 5.191

4.  Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin.

Authors:  George Sakoulas; Jeff Alder; Claudie Thauvin-Eliopoulos; Robert C Moellering; George M Eliopoulos
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

5.  Case-control study of the relationship between MRSA bacteremia with a vancomycin MIC of 2 microg/mL and risk factors, costs, and outcomes in inpatients undergoing hemodialysis.

Authors:  Darego O Maclayton; Katie J Suda; Krista A Coval; Cynthia B York; Kevin W Garey
Journal:  Clin Ther       Date:  2006-08       Impact factor: 3.393

6.  Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy.

Authors:  Pamela A Moise-Broder; George Sakoulas; George M Eliopoulos; Jerome J Schentag; Alan Forrest; Robert C Moellering
Journal:  Clin Infect Dis       Date:  2004-05-21       Impact factor: 9.079

Review 7.  Mechanisms of antibiotic resistance in Staphylococcus aureus.

Authors:  Annalisa Pantosti; Andrea Sanchini; Monica Monaco
Journal:  Future Microbiol       Date:  2007-06       Impact factor: 3.165

8.  Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia.

Authors:  George Sakoulas; Pamela A Moise-Broder; Jerome Schentag; Alan Forrest; Robert C Moellering; George M Eliopoulos
Journal:  J Clin Microbiol       Date:  2004-06       Impact factor: 5.948

9.  Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing.

Authors:  Michael M Mwangi; Shang Wei Wu; Yanjiao Zhou; Krzysztof Sieradzki; Herminia de Lencastre; Paul Richardson; David Bruce; Edward Rubin; Eugene Myers; Eric D Siggia; Alexander Tomasz
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-21       Impact factor: 11.205

10.  Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05.

Authors:  Gregory Steinkraus; Roger White; Lawrence Friedrich
Journal:  J Antimicrob Chemother       Date:  2007-07-10       Impact factor: 5.790

View more
  6 in total

1.  Trends in the susceptibility of methicillin-resistant Staphylococcus aureus to nine antimicrobial agents, including ceftobiprole, nemonoxacin, and tyrothricin: results from the Tigecycline In Vitro Surveillance in Taiwan (TIST) study, 2006-2010.

Authors:  Y-H Chen; C-Y Liu; W-C Ko; C-H Liao; P-L Lu; C-H Huang; C-T Lu; Y-C Chuang; S-M Tsao; Y-S Chen; Y-C Liu; W-Y Chen; T-N Jang; H-C Lin; C-M Chen; Z-Y Shi; S-C Pan; J-L Yang; H-C Kung; C-E Liu; Y-J Cheng; J-W Liu; W Sun; L-S Wang; K-W Yu; P-C Chiang; M-H Lee; C-M Lee; G-J Hsu; P-R Hsueh
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-08-18       Impact factor: 3.267

2.  Outcomes with daptomycin in the treatment of Staphylococcus aureus infections with a range of vancomycin MICs.

Authors:  Jason A Crompton; Donald S North; MinJung Yoon; Judith N Steenbergen; Kenneth C Lamp; Graeme N Forrest
Journal:  J Antimicrob Chemother       Date:  2010-06-16       Impact factor: 5.790

Review 3.  Selection of appropriate analytical tools to determine the potency and bioactivity of antibiotics and antibiotic resistance.

Authors:  Nishant A Dafale; Uttam P Semwal; Rupak K Rajput; G N Singh
Journal:  J Pharm Anal       Date:  2016-05-24

4.  A Single Step in vitro Bioassay Mimicking TLR4-LPS Pathway and the Role of MD2 and CD14 Coreceptors.

Authors:  Pramod Jagtap; Puja Prasad; Abhishek Pateria; Sachin D Deshmukh; Shalini Gupta
Journal:  Front Immunol       Date:  2020-01-24       Impact factor: 7.561

5.  Multicenter Cohort Study of Ceftaroline Versus Daptomycin for Treatment of Methicillin-Resistant Staphylococcus aureus Bloodstream Infection.

Authors:  Evan J Zasowski; Trang D Trinh; Kimberly C Claeys; Abdalhamid M Lagnf; Sahil Bhatia; Kenneth P Klinker; Michael P Veve; Sandy J Estrada; Scott T Johns; Adam J Sawyer; Vanthida Huang; Brandi LaFrance; Donald P Levine; Keith S Kaye; Susan L Davis; Michael J Rybak
Journal:  Open Forum Infect Dis       Date:  2021-12-23       Impact factor: 3.835

6.  Analysis of the Effect of Antibiotic Bone Cement in the Treatment of Diabetic Foot Ulcer through Tibia Transverse Transport.

Authors:  Xiaofang Ding; Yusong Yuan; Hao Lu; Yuanli Wang; Kunyu Ji; Haorun Lv; Hailin Xu; Junlin Zhou
Journal:  Orthop Surg       Date:  2022-08-05       Impact factor: 2.279

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.